DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ENTERO HEALTHCARE SOLU L (ENTERO) share price today?

ENTERO HEALTHCARE SOLU L (ENTERO) is trading at ₹1,174 on the NSE, down 2.60% on the day. Source: DocStoX.

What is the PE ratio of ENTERO HEALTHCARE SOLU L?

ENTERO HEALTHCARE SOLU L has a price-to-earnings (PE) ratio of 44.4 in the Consumer Services sector.

What is the market capitalisation of ENTERO HEALTHCARE SOLU L?

ENTERO HEALTHCARE SOLU L has a market capitalisation of approximately ₹5,129 crore.

ENTERO HEALTHCARE SOLU L

ENTERO·NSE·Consumer Services

₹1,174.00▼ -31.40 (-2.60%)

Consumer Services · Pharmacy Retail

Revenue compounding 26% a year

Day₹1169.10

₹1211.60

52W₹944

₹139052%

Open

₹1205.00

High

₹1211.60

Low

₹1169.10

Prev Close

₹1205.40

Volume

53.4K

VWAP

₹1181.65

Snapshot

Key fundamentals

Market Cap

₹5,129 Cr

P/E Ratio

44.40Expensive

P/B Ratio

3.08

EPS

₹26.44

Book Value

₹388.00

ROE

6.99%Weak

ROCE

11.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.40Moderate

Face Value

₹10.00

52W High

₹1390.00

52W Low

₹944.00

Sector

Consumer Services

Industry

Pharmacy Retail

Avoid

None moatMedium uncertainty

Fair value estimate

₹386

▼ 67.1%downside

Trading at ₹1,174 — 67% above our estimate

BearFair valueBull

₹328₹386₹480

/100

Business quality — Watch the fundamentals

Growth 100Profitability 6Efficiency 8Valuation 47

Plain English

Our view

Revenue compounding 26% a year
Low debt relative to equity
Weak returns on equity (7%)

Strengths

Low debt relative to equity
Revenue compounding 26% over 3 years
Promoters hold a controlling stake

Risks

Weak returns on equity (7%)
Fundamental red flags (Piotroski 0/9)

How we got there

Fair value methods

Residual income

7% ROE fading to 13% over ~3 yrs, on ₹388 book

₹360

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹480

Analyst target

No analyst coverage

—

Blended fair value₹386

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Revenue compounding 26% over 3 years
Promoters hold a controlling stake

Bear case

Weak returns on equity (7%)
Fundamental red flags (Piotroski 0/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

44.4Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

7.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

11.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.40Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹5,129 Cr

P/B

3.08

EPS

₹26.44

Div Yield

—

What changed

Recent changes

Foreign investors-1.1% stake last quarter
Domestic institutions+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 44.4×

Growth

Strong

+26% rev CAGR

Profitability

Modest

7.0% ROE

Financial health

Comfortable

D/E 0.40

Momentum

N/A

No technicals

Today

Trading activity

Delivery %59.7%

Turnover₹630.95L Cr

Trades9,632

VWAP₹1181.65

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+25.9%

+30.0%

10Y

—

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 57.5% CAGR over last 5 years

Watch-outs

Cons

Stock is trading at 3.12 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 6.07% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 1.11 pts; domestic institutions added 0.20 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

52%

Promoter

Promoters

52.4%0.00

Public

26.9%+0.91

FII / FPI

4.0%-1.11

DII

16.6%+0.20

Total shareholders

39,083-1,249 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter52.42%

FII4.03%

DII16.62%

Public26.94%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services[1]